{"url_path":"/sec/fblg/8-k/2026-07-09/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-09","source_url":"https://www.sec.gov/Archives/edgar/data/1958777/0001193125-26-299290-index.html","accession_number":"0001193125-26-299290","cik":"0001958777","ticker":"FBLG","issuer_name":"FibroBiologics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1958777/0001193125-26-299290-index.html","primary_entity_key":"0001958777","primary_entity_name":"FibroBiologics, Inc."},"word_count":376,"has_tables":true,"body_markdown":"## Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.\n\nOn July 2, 2026, Matt Link notified FibroBiologics, Inc. (the “Company”) that he was resigning from the Board of Directors (the “Board”), effective as of July 2, 2026.\n\n \n\nOn July 8, 2026, the Board appointed Kathleen Rubins, Ph.D. as a Class III director of the Board, effective July 8, 2026, to serve until the expiration of her term at the 2029 annual meeting of stockholders. Dr. Rubins was also appointed to serve on the Board’s Audit Committee, Compensation Committee and Governance and Nominating Committee.\n\n \n\nDr. Rubins is the Founding Director, Trivedi Institute for Space and Global Biomedicine, and a Professor of Computational and Systems Biology at the University of Pittsburgh School of Medicine. She is also a US Army Reserve Innovation Officer, Major/O-4 in the 75th US Army Innovation Command. From August 2009 through July 2025, Dr. Rubins served as an Astronaut in the National Aeronautics and Space Administration (NASA). Dr. Rubins received her Ph.D. in Cancer Biology from Stanford University and a Bachelor of Science in Molecular Biology from the University of California, San Diego (UCSD).\n\n \n\nIn connection with her appointment, Dr. Rubins will be entitled to receive compensation consistent with that of the Company’s other non-employee directors under the Company’s Non-Employee Director Compensation Policy, as such policy may be amended from time to time.\n\n \n\nDr. Rubins is not a party to any transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K, and there are no arrangements or understandings between Dr. Rubins and any other persons pursuant to which she was selected as a director.\n\n \n\nThe Company also entered into its standard form of indemnification agreement with Dr. Rubins, which will require the Company to indemnify Dr. Rubins against certain liabilities that may arise as a result of her status or service as a director of the Company. The description of the Company’s standard form of indemnification agreement is qualified in its entirety by reference to the full text of the form of indemnification agreement, a copy of which is filed as Exhibit 10.19 to the Company’s Annual Report on Form 10-K filed with the SEC on February 24, 2026."}